Synthesis and Preliminary Evaluation of N-Oxide Derivatives for the Prevention of Atherothrombotic Events
Leandro Augusto Rosseto,
Maria Elisa Lopes Pires,
Aylime Castanho Bolognesi Melchior,
Priscila Longhin Bosquesi,
Aline Renata Pavan,
Sisi Marcondes,
Man Chin Chung,
Jean Leandro dos Santos
Affiliations
Leandro Augusto Rosseto
Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Jaú Km 01, 14801-902, Araraquara, SP, Brazil
Maria Elisa Lopes Pires
Departmento de Farmacologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, UNICAMP, Rua Tessália Vieira de Camargon.126, 13083-887, Campinas, SP, Brazil
Aylime Castanho Bolognesi Melchior
Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Jaú Km 01, 14801-902, Araraquara, SP, Brazil
Priscila Longhin Bosquesi
Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Jaú Km 01, 14801-902, Araraquara, SP, Brazil
Aline Renata Pavan
Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Jaú Km 01, 14801-902, Araraquara, SP, Brazil
Sisi Marcondes
Departmento de Farmacologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, UNICAMP, Rua Tessália Vieira de Camargon.126, 13083-887, Campinas, SP, Brazil
Man Chin Chung
Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Jaú Km 01, 14801-902, Araraquara, SP, Brazil
Jean Leandro dos Santos
Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, UNESP, Rodovia Araraquara Jaú Km 01, 14801-902, Araraquara, SP, Brazil
Thrombosis is the main outcome of many cardiovascular diseases. Current treatments to prevent thrombotic events involve the long-term use of antiplatelet drugs. However, this therapy has several limitations, thereby justifying the development of new drugs. A series of N-oxide derivatives (furoxan and benzofuroxan) were synthesized and characterized as potential antiplatelet/antithrombotic compounds. All compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) inhibited platelet aggregation induced by adenosine-5-diphosphate, collagen, and arachidonic acid. All compounds protected mice from pulmonary thromboembolism induced by a mixture of collagen and epinephrine; however, benzofuroxan derivatives (13a,b and 14a,b) were the most active compounds, reducing thromboembolic events by up to 80%. N-oxide derivative 14a did not induce genotoxicity in vivo. In conclusion, 14a has emerged as a new antiplatelet/antithrombotic prototype useful for the prevention of atherothrombotic events.